OPGEN, INC. (NASDAQ:OPGN) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.
On June 15, 2017, OpGen, Inc. (the “Company”) entered into a
Supply Agreement (the “Agreement”) with Life Technologies
Corporation, a Thermo Fisher Scientific company (“LTC”), to
which the Company is authorized to lease or purchase LTC
QuantStudio 5 real-time PCR instruments for placement with the
Company’s research use only and, upon receipt of regulatory
approval, commercial customers of the Company’s Acuitas Rapid
Test and Acuitas Lighthouse Knowledgebase products and services
in development. The Agreement also contemplates the placement of
the LTC instruments in Company customer locations using the
Company’s Acuitas Rapid Test and Acuitas Lighthouse
Knowledgebase products and services, once developed and offered.
The Company currently expects such customer commercial activities
to begin in the fourth quarter of 2017.
The Company is responsible for all regulatory matters and filings
seeking regulatory clearance and approval with respect to its
products in development. The Agreement sets forth the
responsibilities of the parties for technical support, software
development and product installation. The term of the Agreement
is three years, with the opportunity to renew for three
successive one-year terms.
The foregoing description of the Agreement is not complete and is
qualified in its entirety by reference to the full text of the
Agreement, a copy of which is filed herewith as Exhibit 10.1 to
this Current Report on Form 8-K and incorporated herein by
reference. A copy of the press release issued by OpGen is
attached as an Exhibit.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
10.1 |
Supply Agreement by and between OpGen, Inc. and Life
Technologies Corporation, dated June 15, 2017 |
99.1 |
Press Release issued by OpGen, Inc., dated June 19, 2017
|
_____________
|
Confidential treatment has been requested for certain
portions of this agreement to an application for confidential treatment filed with the Securities and Exchange Commission on June 19, 2017. Such provisions have been filed separately with the Commission. |
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
OPGEN, INC. |
|||
|
Date: June 19, 2017 |
By: |
/s/ Timothy C. Dec |
|
Timothy C. Dec |
|||
| Chief Financial Officer | |||
EXHIBIT INDEX
|
Exhibit No. |
Description |
|
10.1 |
Supply Agreement by and between OpGen, Inc. and Life Technologies Corporation, dated June 15, 2017 |
|
99.1 |
Press Release issued by OpGen, Inc., dated June 19, 2017 |
_______________
|
Confidential treatment has been requested for certain
portions of this agreement |
OPGEN INC ExhibitEX-10.1 2 ex10x1.htm EXHIBIT 10.1 Exhibit 10.1 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH “*” AND BRACKETS AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. SUPPLY AGREEMENT This Supply Agreement (this “Agreement”) is made effective as of June 15,…To view the full exhibit click here About OPGEN, INC. (NASDAQ:OPGN)
OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company’s high-resolution DNA tests are marketed under the Acuitas trade name.
